Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Najat Bouchkouj"'
Publikováno v:
Hematology/Oncology Clinics of North America. 36:687-699
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a651d884a84d8effe8e3c151f340baf7
https://doi.org/10.1016/j.hoc.2022.03.004
https://doi.org/10.1016/j.hoc.2022.03.004
Autor:
Najat Bouchkouj, Megan Zimmerman, Yvette L Kasamon, Cong Wang, Tianjiao Dai, Zhenzhen Xu, Xiaofei Wang, Marc Theoret, Tejashri Purohit-Sheth, Bindu George
Publikováno v:
Oncologist
In March 2021, the U.S. Food and Drug Administration granted accelerated approval to axicabtagene ciloleucel, a CD19-directed chimeric antigen receptor T-cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36c679d101df2c4e8b231ab8728b3e3d
https://doi.org/10.1093/oncolo/oyac054
https://doi.org/10.1093/oncolo/oyac054
Autor:
Elizabeth Fox, Michael Berntgen, Alfonso Quintás-Cardama, Veronique Minard-Colin, Susan L. Weiner, André Baruchel, Laura Pearce, Karsten Nysom, Andrew D.J. Pearson, Danielle H. Taylor, Christian M. Zwaan, Nirali N. Shah, Yousif Matloub, Ivan D. Horak, Gregory H. Reaman, Gilles Vassal, Koen Norga, Claudia Rossig, Dominik Karres, Lori A. Ehrlich, Martina Schüßler-Lenz, Alberto S. Pappo, Joe McDonough, Martina A. Sersch, Nick Richardson, Donna Ludwinski, Abraham Bassan, Eric Bleickardt, Nicole Scobie, Stephen Gottschalk, Rob Pieters, Sarah K. Tasian, Courtney Johnson, Teresa de Rojas, Malcolm A. Smith, Franca Ligas, Lynley V. Marshall, Shannon L. Maude, Brenda J. Weigel, Nick Bird, Najat Bouchkouj, Behzad K. Masouleh, Sarah Beaussant Cohen, Delphine Heenen, Rosanna Ricafort, G. Lesa, Linda Hanssens, Peter F. Bross, Carrie Brownstein, Crystal L. Mackall, Martin Pule, Douglas S. Hawkins, Jaroslav Sterba, Maksim Mamonkin
Publikováno v:
European Journal of Cancer. 160:112-133
The seventh multi-stakeholder Paediatric Strategy Forum focused on chimeric antigen receptor (CAR) T-cells for children and adolescents with cancer. The development of CAR T-cells for patients with haematological malignancies, especially B-cell precu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::109dc83dd17c2fd2077a3e812e4df67f
https://doi.org/10.1016/j.ejca.2021.10.016
https://doi.org/10.1016/j.ejca.2021.10.016
Autor:
Najat Bouchkouj, Xue Lin, Xiaofei Wang, Donna Przepiorka, Zhenzhen Xu, Tejashri Purohit-Sheth, Marc Theoret
Publikováno v:
Oncologist
In October 2021, the FDA approved brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9232ed36dce588d8590c73dc37bfa1e
https://europepmc.org/articles/PMC9526496/
https://europepmc.org/articles/PMC9526496/
Publikováno v:
Hematology/oncology clinics of North America. 36(4)
The recent progress in gene and gene-modified cellular therapies has shown great promise for numerous pediatric diseases. Nevertheless, the development of these products is complicated, and the regulatory pathway is rigorous. There are, however, seve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::59c6a902f0277245979448870b26bd07
https://pubmed.ncbi.nlm.nih.gov/35773050
https://pubmed.ncbi.nlm.nih.gov/35773050
Autor:
Andrew Dj, Pearson, Claudia, Rossig, Crystal, Mackall, Nirali N, Shah, Andre, Baruchel, Gregory, Reaman, Rosanna, Ricafort, Delphine, Heenen, Abraham, Bassan, Michael, Berntgen, Nick, Bird, Eric, Bleickardt, Najat, Bouchkouj, Peter, Bross, Carrie, Brownstein, Sarah Beaussant, Cohen, Teresa, de Rojas, Lori, Ehrlich, Elizabeth, Fox, Stephen, Gottschalk, Linda, Hanssens, Douglas S, Hawkins, Ivan D, Horak, Danielle H, Taylor, Courtney, Johnson, Dominik, Karres, Franca, Ligas, Donna, Ludwinski, Maksim, Mamonkin, Lynley, Marshall, Behzad K, Masouleh, Yousif, Matloub, Shannon, Maude, Joe, McDonough, Veronique, Minard-Colin, Koen, Norga, Karsten, Nysom, Alberto, Pappo, Laura, Pearce, Rob, Pieters, Martin, Pule, Alfonso, Quintás-Cardama, Nick, Richardson, Martina, Schüßler-Lenz, Nicole, Scobie, Martina A, Sersch, Malcolm A, Smith, Jaroslav, Sterba, Sarah K, Tasian, Brenda, Weigel, Susan L, Weiner, Christian Michel, Zwaan, Giovanni, Lesa, Gilles, Vassal
Publikováno v:
European journal of cancer
European journal of cancer, 160:112-133
European journal of cancer, 160:112-133
The seventh multi-stakeholder Paediatric Strategy Forum focused on chimeric antigen receptor (CAR) T-cells for children and adolescents with cancer. The development of CAR T-cells for patients with haematological malignancies, especially B-cell precu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::7e4b2ff665e9b497893f3198ef4554c2
https://repository.uantwerpen.be/docstore/d:irua:12922
https://repository.uantwerpen.be/docstore/d:irua:12922
Autor:
Shiowjen Lee, Yvette L. Kasamon, Wilson Bryan, Bindu George, Amy E. McKee, Xue Lin, Najat Bouchkouj, Gideon M. Blumenthal, Richard Pazdur, R. Angelo de Claro
Publikováno v:
Clinical Cancer Research. 25:1702-1708
In October 2017, the FDA granted regular approval to axicabtagene ciloleucel, a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fe8d19268ba116094553fea320b0db9
https://doi.org/10.1158/1078-0432.ccr-18-2743
https://doi.org/10.1158/1078-0432.ccr-18-2743
Autor:
Meena N Murugappan, Najat Bouchkouj, Paul G. Kluetz, Erica G. Horodniceanu, Vishal Bhatnagar, Bellinda L King-Kallimanis, Gregory H. Reaman
Publikováno v:
J Natl Cancer Inst
Pediatric patient-reported outcome (PRO) data can help inform the US Food and Drug Administration’s (FDA’s) benefit-risk assessment of cancer therapeutics by quantifying symptom and functional outcomes from the patient’s perspective. This study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aacd0515e89e52d115dc1f286e0b6c60
https://pubmed.ncbi.nlm.nih.gov/33930159
https://pubmed.ncbi.nlm.nih.gov/33930159
Autor:
Janice Kim, Jessica K Roydhouse, Paul G. Kluetz, Ann T. Farrell, Najat Bouchkouj, Hussein Ezzeldin, Bindu Kanapuru
Publikováno v:
Blood. 134:3450-3450
Introduction: In recent years, there has been increased interest in patient experience data, including PROs. To determine how and where PRO data are being assessed and communicated as part of approval of a marketing application, we examined approvals
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a0db10f66cdd4f391a94ff44832f8f43
https://doi.org/10.1182/blood-2019-125798
https://doi.org/10.1182/blood-2019-125798
Autor:
Terry J. Fry, Jack H. Lai, Barry Jones, Iwona Woznica, Yuxin Liu, Najat Bouchkouj, Shannon M. Larabee, Haiying Qin, Crystal L. Mackall, Brynn B. Duncan, Steven L. Highfill, William W. Bachovchin, Wengen Wu, Youhua Li, Peng Zhao
Publikováno v:
Journal of Immunotherapy. 36:400-411
Current multimodality therapy consisting of surgery, chemotherapy and radiation will fail in approximately 40% of patients with pediatric sarcomas and results in substantial long-term morbidity in those who are cured. Immunotherapeutic regimens for t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d996705bfeaec398597b301cbb120a20
https://doi.org/10.1097/cji.0b013e3182a80213
https://doi.org/10.1097/cji.0b013e3182a80213